Report From J-PULSE Multicenter Registry of Patients With Shock-Resistant Out-of-Hospital Cardiac Arrest Treated With Nifekalant Hydrochloride-Reference-Cited by-同舟云学术

Report From J-PULSE Multicenter Registry of Patients With Shock-Resistant Out-of-Hospital Cardiac Arrest Treated With Nifekalant Hydrochloride

Published:2010 Issue:11 Volume:74 Page:2308-2313
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Yasuda Satoshi¹²,Sawano Hirotaka³,Hazui Hiroshi⁴,Ukai Isao⁵,Yokoyama Hiroyuki¹,Ohashi Junko¹²,Sase Kazuhiro⁶,Kada Akiko¹,Nonogi Hiroshi¹,The J-PULSE Investigators

Affiliation:

1. National Cerebral and Cardiovascular Center

2. Tohoku University Graduate School of Medicine

3. Saiseikai Senri Hospital, Senri Critical Care Medical Center

4. Osaka Mishima Emergency and Critical Care Center

5. Osaka University Hospital Trauma and Acute Critical Care Center

6. Juntendo University Medical School

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://www.jstage.jst.go.jp/article/circj/74/11/74_CJ-09-0759/_pdf

Reference24 articles.

1. 1. Nichol G, Rumsfeld J, Eigel B, Abella BS, Labarthe D, Hong Y, et al. Essential features of designating out-of-hospital cardiac arrest as a reportable event: A scientific statement from the American Heart Association Emergency Cardiovascular Care Committee; Council on Cardiopulmonary, Perioperative, and Critical Care; Council on Cardiovascular Nursing; Council on Clinical Cardiology; and Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2008; 117: 2299-2308.

2. Amiodarone for Resuscitation after Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation

3. Amiodarone as Compared with Lidocaine for Shock-Resistant Ventricular Fibrillation

4. Cellular electrophysiological effects of MS-551, a new class III antiarrhythmic agent

5. 5. Oyabe H, Sano H. Pharmacological and clinical profile of nifekalant (shinbit(R) injection), a class III antiarrhythmic drug. Folia Pharmacol Jpn 2003; 119: 103-109.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anesthetic management of a patient with severe aortic regurgitation undergoing reoperation for ascending aorta false aneurysm using hypothermia: prevention of ventricular fibrillation by nifekalant;JA Clinical Reports;2021-05-20

2. Nifekalant;JACC: Case Reports;2020-02

3. Drug Therapy for Shock-Resistant Ventricular Fibrillation: Comparison of Nifekalant and Amiodarone;Journal of UOEH;2016

4. Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation;Cardiovascular Drugs and Therapy;2015-07-07

5. Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation;Journal of Anesthesia;2014-01-05